Evexomostat combination shows clinical benefit and favorable safety in heavily pretreated HR+/HER2− mBC patients with ...
Spatial transcriptomic and proteomic insight into Trop-2, HER2, and AR expression: A pathway to tailored therapies in triple-negative breast cancer. This is an ASCO Meeting Abstract from the 2024 ASCO ...
Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline across key clinical milestones in endometrial and breast cancer PIKTOR is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results